SURAKSHA2024-10-012024-12-31 SURAKSHA2024-10-012024-12-31 SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses04Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses05Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses06Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses07Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses08Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses09Member SURAKSHA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses10Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses04Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses05Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses06Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses07Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses08Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses09Member SURAKSHA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses10Member SURAKSHA2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544293 SURAKSHA NA Suraksha Diagnostic Limited Equity 2024-04-01 2025-03-31 2025-02-08 2025-02-03 INR Lakhs Third quarter 16:00:00 16:32:00 2025-02-08 2025-02-08 Not applicable Single segment DIAGNOSTIC 2024-10-01 2024-12-31 Unaudited Standalone 585700000.00 9745000.00 595445000.00 59882000.00 0.00 0.00 110142000.00 20329000.00 86155000.00 234747000.00 511255000.00 84190000.00 0.00 84190000.00 21541000.00 -920000.00 20621000.00 0.00 63569000.00 0.00 0.00 0.00 0.00 63569000.00 1224000.00 64793000.00 0.00 0.00 104162000.00 2 1.22 1.22 0.00 0.00 1.22 1.22 1. The unaudited standalone financial results for the quarter and nine months period ended December 31, 2024 (“the financial results”) of Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) (“the Company”) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing) Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the regulations”). 2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on February 08, 2025. The statutory auditors have carried out limited review on these financial results and have issued an unmodified conclusion. 3. The figures for the corresponding quarter and nine months period ended December 31, 2023 are presented based on the information complied by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However, the management has prepared the results for the said periods by applying consistent accounting policies. 4. During the quarter ended December 31, 2024, the Company has completed an initial Public Offering entirely as offer for sale of 1,91,89,330 equity shares by existing share holders with face value of Rs.2 and listed on both National Stock exchange (NSE) and Bombay Stock Exchange (BSE) on December 06, 2024. 6. The figures for the year ended March 31, 2024 have been extracted from the general purpose standalone financial statements of the Company which were audited by the statutory auditors of the Company. 7. During the quarter ended December 31, 2024, 0.0001% Compulsorily Convertible Preference Shares aggregating to 1,62,859 preference shares of par value Rs 100 each were converted into 89,55,761 equity shares of par value of Rs 2 each. 8. During the quarter ended December 31, 2024, the Nomination and Remuneration Committee ( the NRC ) has approved grant of 2,08,164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024 ( the Scheme ). The Company has accounted for these stock options in accordance with Ind AS 102 – Share-Based Payments 9. These financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com). Single segment 2024-04-01 2024-12-31 Unaudited Standalone 1849503000.00 34409000.00 1883912000.00 203565000.00 0.00 0.00 319106000.00 63220000.00 260690000.00 699140000.00 1545721000.00 338191000.00 0.00 338191000.00 88230000.00 -4372000.00 83858000.00 0.00 254333000.00 0.00 0.00 0.00 0.00 254333000.00 -1405000.00 252928000.00 0.00 0.00 104162000.00 2 4.88 4.88 0.00 0.00 4.88 4.88 Advertisement 9071000.00 Commission to collection centers 9906000.00 Information technology expenses 13558000.00 Other Expenses 32673000.00 Power and fuel 20742000.00 Professional fees paid to doctors 96945000.00 Rent 10145000.00 Repairs and maintenance 18958000.00 Sample testing and collection charges 8552000.00 Security and housekeeping charges 14197000.00 Advertisement 25585000.00 Commission to collection centers 28654000.00 Information technology expenses 37612000.00 Other Expenses 89712000.00 Power and fuel 61583000.00 Professional fees paid to doctors 304812000.00 Rent 26935000.00 Repairs and maintenance 58485000.00 Sample testing and collection charges 25282000.00 Security and housekeeping charges 40480000.00 1224000.00 -1405000.00 0.00 0.00 0.00 0.00